
Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target
Arcutis Biotherapeutics (ARQT) Analyst Ratings
Bulls say
Arcutis Biotherapeutics Inc. is poised for strong growth, evidenced by a projected 4% price increase for the Zoryve franchise and impressive near-term prescription growth of approximately 12% quarter over quarter. The company's product revenue for Zoryve reached $69.4 million in the fourth quarter, surpassing early estimates and indicating a robust sales trajectory driven by the launch of Zoryve foam and cream formulations. Management is optimistic about sustained revenue growth in 2025 and beyond, supported by new indications and label extensions that position Zoryve as a leading treatment option among dermatologists for various skin conditions.
Bears say
Arcutis Biotherapeutics Inc. has reported a significant decline in R&D expenses, which fell by 39.1% year-over-year to $14.5 million, indicating potential challenges in maintaining momentum for its product development despite previous trial successes. The company also recorded a net loss of $10.8 million in the fourth quarter of 2024, resulting in a diluted loss per share of $0.09, which was lower than previously estimated and reflects the ongoing financial strain as it navigates increasing operating expenses without providing operational expenditure guidance. Additional risks, such as reliance on a third party for manufacturing Zoryve and the highly competitive dermatology market, further contribute to a cautious outlook regarding the company’s future commercial success and overall financial health.
This aggregate rating is based on analysts' research of Arcutis Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
Arcutis Biotherapeutics (ARQT) Analyst Forecast & Price Prediction
Start investing in Arcutis Biotherapeutics (ARQT)
Order type
Buy in
Order amount
Est. shares
0 shares